Smallpox - Pipeline Review, H1 2018

  • ID: 4455933
  • Report
  • 73 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • BioFactura Inc
  • CEL-SCI Corp
  • Chimerix Inc
  • EpiVax Inc
  • SIGA Technologies Inc
  • MORE
Smallpox - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H1 2018, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Smallpox - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 2, 6 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • BioFactura Inc
  • CEL-SCI Corp
  • Chimerix Inc
  • EpiVax Inc
  • SIGA Technologies Inc
  • MORE
Introduction

Smallpox - Overview

Smallpox - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Smallpox - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smallpox - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

EpiVax Inc

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Smallpox - Drug Profiles

24a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brincidofovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious disease vaccines - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Smallpox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox [ankara] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecovirimat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIR-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smallpox - Dormant Projects

Smallpox - Discontinued Products

Smallpox - Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox

Nov 21, 2017: Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine

Sep 27, 2017: Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government

Sep 20, 2017: SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27,

Jun 16, 2017: Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE

May 31, 2017: SIGA to Present at the Jefferies Global Healthcare Conference on June 9,

Apr 20, 2017: SIGA Completes Enrollment and Dosing in Final Cohort of Phase I Study of IV Formulation of TPOXX (tecovirimat) to Treat Smallpox

Mar 02, 2017: Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus

Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-801 at 9th Annual Biotech Showcase Conference

Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects

Nov 23, 2016: Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE Smallpox Vaccine

Sep 21, 2016: SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full

Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government

Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral

Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Smallpox, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Smallpox - Pipeline by Bavarian Nordic A/S, H1

Smallpox - Pipeline by BioFactura Inc, H1

Smallpox - Pipeline by CEL-SCI Corp, H1

Smallpox - Pipeline by Chimerix Inc, H1

Smallpox - Pipeline by EpiVax Inc, H1

Smallpox - Pipeline by SIGA Technologies Inc, H1

Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H1

Smallpox - Dormant Projects, H1

Smallpox - Discontinued Products, H1

List of Figures

Number of Products under Development for Smallpox, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bavarian Nordic A/S
  • BioFactura Inc
  • CEL-SCI Corp
  • Chimerix Inc
  • EpiVax Inc
  • SIGA Technologies Inc
  • Tonix Pharmaceuticals Holding Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll